Asset Details
Do you wish to reserve the book?
Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson’s Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson’s Disease
Do you wish to request the book?
Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson’s Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson’s Disease
2025
Overview
Foslevodopa/foscarbidopa [PRODUODOPA
(EU); VYALEV
(USA, Canada, Japan)] is a soluble formulation of levodopa and carbidopa prodrugs for 24-h continuous subcutaneous (SC) infusion. It is approved for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). Administered via an ambulatory infusion pump, it allows for personalized dosing based on individual needs. In a randomized, double-blind, double-dummy trial, continuous SC infusion of foslevodopa/foscarbidopa provided a significant and clinically meaningful increase in hours of 'on' time without troublesome dyskinesia and a reduction in hours of 'off' time compared with oral immediate-release levodopa/carbidopa. The benefits of foslevodopa/foscarbidopa were maintained over the longer term (up to 124 weeks). Continuous SC infusion of foslevodopa/foscarbidopa was generally well tolerated, including over the longer term. However, infusion site events were common, necessitating regular monitoring, cannula replacement, infusion site rotation and aseptic techniques. Although further long-term data are required, foslevodopa/foscarbidopa represents a promising non-surgical alternative to the available device-aided therapies for patients with advanced PD whose motor fluctuations are inadequately controlled by other oral PD medications.
Publisher
Springer Nature B.V
Subject
Antiparkinson Agents - administration & dosage
/ Antiparkinson Agents - adverse effects
/ Antiparkinson Agents - therapeutic use
/ Carbidopa - administration & dosage
/ Dopamine
/ Humans
/ Levodopa
/ Levodopa - administration & dosage
/ Parkinson Disease - drug therapy
/ Parkinson Disease - physiopathology
/ Patients
/ Plasma
